Comparison of outcomes of neoadjuvant chemotherapy in <i>BRCA1</i>- versus <i>BRCA2</i>-associated breast and ovarian cancers.

ABSTRACT:

Aim

BRCA1/2-associated breast and ovarian carcinomas are often regarded as a single entity, assuming that BRCA1 and BRCA2 genes are almost equivalent with regard to their clinical significance. However, BRCA1 and BRCA2 genes differ in their function; therefore, a comparison of treatment outcomes in BRCA1 vs. BRCA2 carriers is warranted.

Methods

This study focused on consecutive patients treated with neoadjuvant chemotherapy (NACT), given that these subjects are treatment-naive and accessible for immediate assessment of pathological and clinical outcomes.

Results

BRCA2-associated high-grade serous ovarian carcinomas (HGSOCs) demonstrated significantly higher rates of pathologic complete response (pCR) as co

SUBMITTER: Sokolenko A 

PROVIDER: S-EPMC12179429 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature